Boothbay Fund Management, LLC Lineage Cell Therapeutics, Inc. Transaction History

Boothbay Fund Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$1.2 - $1.53 $559 - $712	466 Added 0.63%	74,560 $111,000
Q4 2022 Feb 14, 2023	BUY	$1.02 - $1.5 $75,575 - $111,141	74,094 New	74,094 $86,000
Q2 2022 Aug 15, 2022	BUY	$1.12 - $1.61 $31,110 - $44,720	27,777 New	27,777 $44,000
Q1 2022 May 16, 2022	SELL	$1.21 - $2.48 $17,252 - $35,359	-14,258 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$1.84 - $2.68 $26,234 - $38,211	14,258 New	14,258 $35,000

132

92.6M

80.9K

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $117M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.